Literature DB >> 6594916

Disability indices, the economic costs of illness, and social insurance: the case of multiple sclerosis.

R P Inman.   

Abstract

Debilitating, long-term illness can impose a significant economic hardship on families affected with the illness and on the wider society as well. In addition to medical research to find a cure or a prevention for such illnesses, society may wish, in the interim, to allocate resources to compensate the families burdened by the illness for the economic losses they have suffered. Such compensation will take the form of a social insurance program. The socially optimal insurance program requires two crucial pieces of information: (i) an index of physical disability and (ii) an accurate assessment of the economic losses associated with each stage of disability as measured by that index. This paper reports on an initial attempt using U.S. data to provide these two important facts for one long-term, disabling illness: multiple sclerosis.

Entities:  

Mesh:

Year:  1984        PMID: 6594916     DOI: 10.1111/j.1600-0404.1984.tb02552.x

Source DB:  PubMed          Journal:  Acta Neurol Scand Suppl        ISSN: 0065-1427


  6 in total

Review 1.  Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.

Authors:  Omar Khan; Rana Zabad; Christina Caon; Marina Zvartau-Hind; Alexandros Tselis; Robert Lisak
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 2.  The economics of multiple sclerosis. Distribution of costs and relationship to disease severity.

Authors:  A N Grudzinski; Z Hakim; E R Cox; J L Bootman
Journal:  Pharmacoeconomics       Date:  1999-03       Impact factor: 4.981

3.  The economic impact of multiple sclerosis to the patients and their families in Norway.

Authors:  B Svendsen; N Grytten; L Bø; H Aarseth; T Smedal; K-M Myhr
Journal:  Eur J Health Econ       Date:  2018-04-21

4.  Multiple sclerosis in Italy: cost-of-illness study.

Authors:  F Patti; M P Amato; M Trojano; C Solaro; A Pappalardo; V Zipoli; E Portaccio; D Paolicelli; A Paolillo; F S Mennini; A Marcellusi; C Ricci; M A Battaglia
Journal:  Neurol Sci       Date:  2011-03-16       Impact factor: 3.307

5.  Economic evaluation of multiple sclerosis in the UK, Germany and France.

Authors:  N Murphy; C Confavreux; J Haas; N König; E Roullet; M Sailer; M Swash; C Young; J L Mérot
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

6.  Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).

Authors:  Uwe K Zettl; Thomas Henze; Ute Essner; Peter Flachenecker
Journal:  Eur J Health Econ       Date:  2013-12-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.